All AbMole products are for research use only, cannot be used for human consumption.
YHO-13177 is a potent and specific inhibitor of breast cancer resistance protein (BCRP/ABCG2). YHO-13177 potentiated the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP.
| Molecular Weight | 370.47 |
| Formula | C20H22N2O3S |
| CAS Number | 912287-56-0 |
| Form | Solid |
| Solubility (25°C) | DMSO ≥ 19 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related BCRP/ABCG2/MXR/ABCP Products |
|---|
| CCTA-1523
CCTA-1523 is a potent, selective, reversible, and orally active ABCG2 inhibitor.CCTA-1523 exhibits cytotoxicity and anticancer activity. |
| Ac32Az19
Ac32Az19 is a potent, nontoxic, and highly selective BCRP inhibitor with an EC50 value of 13 nM in BCRP overexpressing HEK293/R2 cells. |
| ML230
ML230 is a selective inhibitor of the ATP-binding transporter subtype ABCG2, and its inhibitory effect on ABCG2 was 36 times that of ABCB1, with EC50 values of 0.13 μM and 4.65 μM, respectively. |
| (S)-ML753286
(S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor that inhibits BCRP efflux transporter protein with an IC50 of 0.6 μM. |
| Efflux inhibitor-1
Efflux inhibitor-1 is a pyrazolo[1,5-a]pyrimidine efflux inhibitor that also selectively targets ABCG2, with IC50s of 0.45 μM and 2.17 μM, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
